Markets
US manufacturing reshoring
On the Ford line, circa 1935 (Corbis/Getty Images)

If re-shoring were happening, Rockwell Automation would know

Its earnings were really good, too.

5/7/25 1:03PM

Rockwell Automation, essentially a maker of high-tech assembly lines, surged on Wednesday after posting results that beat analyst expectations and upgrading its outlook for earnings per share — after months of declining expectations from Wall Street.

It’s a healthy move for a stock that’s gone largely nowhere for the last couple years, a cooling-off period following a surge of outperformance during the Covid-era supply chain disruptions, labor shortages, and surging inflation, all of which prompted companies to boost spending on automation processes to increase efficiency.

In theory, the Trump administration’s push to reinvigorate US manufacturing — one of the many explanations the White House offers for its fixation on tariffs — should benefit companies like Rockwell, which could help build those factories. But that’s only if the uncertainty generated by the White House’s on-again, off-again approach to tariffs doesn’t paralyze investment and cause a recession.

Rockwell CEO Blake Moret offered some interesting thoughts on those dynamics in the company’s post-earnings conference call.

“The current trade and policy uncertainty has impacted some large capex projects across our customer base. We saw some project delays in automotive and energy and some deferrals of more discretionary spend in digital services,” Moret said. “These customers are seeking additional certainty about the impact tariffs will have on their cost base and whether the volatility will impact their demand.”

Analysts followed up in the Q&A section of the call, which we edited, condensed, and excerpted below:

Scott Davis, Melius Research: You guys are sitting in a position of having the most visibility into this balance between re-shoring acceleration and the macro realities and concerns folks are having. How are your customers thinking through that? Are they accelerating re-shoring? Are they hunkering down?

Moret: There is still a generally optimistic long-term view among most of our customers, especially those with high exposure to the US, because the idea of US manufacturing as a good thing for the US economy resonates with a lot of us. And of course, Rockwell is a net beneficiary of that.

Where we are seeing delays, as we analyze the projects that haven't moved forward, the underlying reasons fall into a few different categories. First is concern about cost certainty, which, you know, a lot of that would come from tariffs. Automotive is obviously affected by that, given the amount of content from around the world there.

We heard some comments regarding interest rates as well.

Another underlying reason would be concerns about the demand from our customers’ end markets. I mentioned lower commodity prices in the US that will affect oil and gas and a little bit of mining.

Chris Snyder, Morgan Stanley: Around the market demand trends, its understandable and makes sense that with all the uncertainty out there, maybe its hard to move forward with a big project if you dont know how much it costs and you dont know if the rules are changing.

But when you guys talk to customers, you know, is there an expectation that as visibility starts to come through, we could see more of these projects unlocking in the coming quarters?

Moret: We actually do expect that these customers are going to pull the trigger on some of these investments. Were not going to call a specific date or quarter on that. But we saw some of those projects come in April, and we think we have a pretty good handle on what theyre grappling with.

All manufacturers are looking for more certainty and consistency with the tariffs and the costs that might come along with tariffs, as well as making sure that the demand is still there from their end customers.

And in the majority of cases, they expect that this is a pause. Not anything that that lasts for a long, long time.

Of course, the length of that “pause” to investment plans is crucial as to whether we have a serious slowdown or recession. Given that the world’s two largest economies are only at the very early stages of potential trade talks, it seems like it could be a while.

More Markets

See all Markets
markets

Robinhood, AppLovin, and Emcor pop on announcement of addition to S&P 500

Shares of Robinhood Markets, AppLovin, and Emcor are all rallying in post-market trading on Friday upon news that they’re being added to the S&P 500.

Shares of the brokerage popped 7.2%, the adtech company rose 7.8%, and the construction company was up a more modest 2.7% in the minutes following the announcement.

(Robinhood Markets, Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions.)

Strategy, another stock rumored to be in the running for inclusion in the benchmark US stock index that has been passed over, sank 2.5% in postmarket trading.

markets

Kenvue plunges after reports suggest RFK Jr. may try to link prenatal Tylenol use to autism

Kenvue sank 15% Friday after a WSJ report said Health and Human Services Secretary Robert F. Kennedy Jr. may attempt to link prenatal Tylenol use to autism in an upcoming government report.

Kenvue, the maker of Tylenol and formerly a division of Johnson & Johnson prior to a 2023 spin-out, pushed back, saying the science shows “no causal link” between acetaminophen use during pregnancy and autism, and pointed to FDA and medical groups that agree on the drug’s safety.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

markets

Lucid surges following 6 days of losses after headlines misidentify Cantor Fitzgerald’s lower split-adjusted price target as a good thing

It’s been a shortened week, but still a rough one for Lucid. Investor blowback to the luxury EV maker’s 1-for-10 reverse stock split has sent shares to all time lows this week.

After six straight days of closing lower, Wall Street appears to have decided enough is enough and is loading up on Lucid shares on Friday, sending them up 13% in recent trading. As of 2:10pm eastern, Lucid trading volumes were at more than 240% of their 30 day average.

Some of the move could be attributed to traders reading headlines that don’t take into consideration Lucid’s reverse split. Cantor Fitzgerald on Friday slapped a new price target on Lucid of $20, compared to its previous target of $3. Some news outlets (not us!) presented that as an increase. The problem: With the 1-for-10 reverse split in effect, a comparable price target would have been $30. The new $20 target is actually... a cut.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.